Tilray Brands, Inc. (2HQ.DE)
EUR 1.16
(0.43%)
EUR 1.16
(0.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 158.97 Million USD | -58.55% |
| 2022 | 383.49 Million USD | 84.47% |
| 2021 | 207.89 Million USD | -53.82% |
| 2020 | 450.19 Million USD | 874.22% |
| 2019 | -58.14 Million CAD | -26.48% |
| 2018 | -45.97 Million CAD | -106.92% |
| 2017 | -22.21 Million CAD | 35.6% |
| 2016 | -34.5 Million CAD | -173.19% |
| 2015 | -12.62 Million CAD | -122.58% |
| 2014 | -5.67 Million CAD | -47751.71% |
| 2013 | -11.85 Thousand CAD | -21.65% |
| 2012 | -9747.68 CAD | 59.1% |
| 2011 | -23.83 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 116.93 Million USD | 0.44% |
| 2023 Q3 | 335.36 Million USD | -13.12% |
| 2023 Q4 | 158.97 Million USD | -52.6% |
| 2023 FY | 158.97 Million USD | -58.55% |
| 2023 Q1 | 385.19 Million USD | 0.44% |
| 2023 Q2 | 386 Million USD | 0.21% |
| 2022 Q3 | 438.73 Million USD | 4.79% |
| 2022 Q1 | 167.17 Million USD | -19.59% |
| 2022 FY | 383.49 Million USD | 84.47% |
| 2022 Q4 | 383.49 Million USD | -12.59% |
| 2022 Q2 | 418.69 Million USD | 150.45% |
| 2021 Q3 | 453.65 Million USD | -3.06% |
| 2021 Q1 | 497.43 Million USD | 10.49% |
| 2021 FY | 207.89 Million USD | -53.82% |
| 2021 Q4 | 207.89 Million USD | -54.17% |
| 2021 Q2 | 467.98 Million USD | -5.92% |
| 2020 FY | 450.19 Million USD | 874.22% |
| 2020 Q2 | 276.89 Million USD | 1368.94% |
| 2020 Q3 | 519.16 Million CAD | 87.5% |
| 2020 Q4 | 450.19 Million USD | -13.29% |
| 2020 Q1 | 18.84 Million USD | 132.42% |
| 2019 FY | -58.14 Million CAD | -26.48% |
| 2019 Q3 | -22.38 Million USD | -481.95% |
| 2019 Q2 | 5.85 Million USD | -68.42% |
| 2019 Q4 | -58.14 Million USD | -159.81% |
| 2019 Q1 | 18.55 Million USD | 140.36% |
| 2018 Q1 | -167.18 Million USD | -652.48% |
| 2018 Q2 | -72.99 Million USD | 56.34% |
| 2018 Q4 | -45.97 Million USD | -100.66% |
| 2018 Q3 | -22.91 Million USD | 68.61% |
| 2018 FY | -45.97 Million CAD | -106.92% |
| 2017 Q3 | -63.23 Million USD | 2.56% |
| 2017 Q2 | -64.89 Million USD | -1451.6% |
| 2017 Q1 | -4.18 Million CAD | 87.88% |
| 2017 FY | -22.21 Million CAD | 35.6% |
| 2017 Q4 | -22.21 Million USD | 64.86% |
| 2016 Q4 | -34.5 Million CAD | 39.77% |
| 2016 Q2 | -67.78 Million CAD | -94.05% |
| 2016 Q1 | -34.92 Million CAD | -176.56% |
| 2016 FY | -34.5 Million CAD | -173.19% |
| 2016 Q3 | -57.28 Million CAD | 15.49% |
| 2015 FY | -12.62 Million CAD | -122.58% |
| 2015 Q1 | -3.76 Million CAD | 33.73% |
| 2015 Q2 | -2.45 Million CAD | 34.65% |
| 2015 Q3 | -8.89 Million CAD | -261.96% |
| 2015 Q4 | -12.62 Million CAD | -41.99% |
| 2014 Q4 | -5.67 Million CAD | 23.19% |
| 2014 FY | -5.67 Million CAD | -47751.71% |
| 2014 Q3 | -7.38 Million CAD | -6556.29% |
| 2014 Q2 | -110.97 Thousand CAD | -835.88% |
| 2014 Q1 | -11.85 Thousand CAD | -76.86% |
| 2013 Q1 | -9747.68 CAD | -601.59% |
| 2013 FY | -11.85 Thousand CAD | -21.65% |
| 2013 Q4 | -6704.57 CAD | 40.9% |
| 2013 Q3 | -11.34 Thousand CAD | -490.72% |
| 2013 Q2 | -1920.54 CAD | 80.3% |
| 2012 FY | -9747.68 CAD | 59.1% |
| 2012 Q1 | -23.83 Thousand CAD | 41.82% |
| 2012 Q2 | -21.87 Thousand CAD | 8.23% |
| 2012 Q3 | -15.24 Thousand CAD | 30.29% |
| 2012 Q4 | -1389.37 CAD | 90.89% |
| 2011 FY | -23.83 Thousand CAD | 0.0% |
| 2011 Q4 | -40.96 Thousand CAD | 11.68% |
| 2011 Q2 | -64.46 Thousand CAD | 0.0% |
| 2011 Q3 | -46.38 Thousand CAD | 28.05% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| MPH Health Care AG | 8.5 Million EUR | -1769.76% |
| Apontis Pharma AG | -20.8 Million EUR | 864.313% |
| Dermapharm Holding SE | 921.66 Million EUR | 82.751% |
| Evotec SE | 115.28 Million EUR | -37.894% |
| MERCK Kommanditgesellschaft auf Aktien | 7.95 Billion EUR | 98.003% |
| PharmaSGP Holding SE | 33.21 Million EUR | -378.688% |
| SynBiotic SE | 3.59 Million EUR | -4327.044% |